NervGen Doses First Participant in Phase 3 RESTORE Study of Neuroreparative Peptide NVG-291 in Chronic Spinal Cord Injury
NVG-291 is a subcutaneously administered peptide designed to target the inhibitory CSPG-PTPσ pathway in adults one to ten years after a traumatic cervical motor-incomplete spinal cord injury.

Key Points
- NervGen has dosed the first participant in RESTORE, a Phase 3 registrational study of its neuroreparative peptide NVG-291 in chronic cervical motor-incomplete spinal cord injury.
- The multicenter, randomized, double-blind, placebo-controlled trial is expected to enroll approximately 150 adults across the United States and Canada.
- NervGen anticipates completing enrollment in the second half of 2027 and reporting topline data in the first half of 2028.
NervGen, a late-stage clinical biopharmaceutical company developing neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, announced that the first participant has been dosed in RESTORE, a Phase 3 registrational study evaluating NVG-291 in individuals living with chronic cervical motor-incomplete spinal cord injury. NVG-291 is a subcutaneously administered neuroreparative peptide designed to target the inhibitory CSPG-PTPσ pathway.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
NervGen anticipates completing enrollment in the second half of 2027 and reporting topline data in the first half of 2028.
“Dosing the first participant in RESTORE marks a critical milestone for NervGen and a major step toward our goal of restoring function and independence for people living with spinal cord injury,” said Adam Rogers, MD, Chief Executive Officer of NervGen. “This progress reflects the expertise and unwavering dedication of our team in building on the compelling clinical results from CONNECT SCI to advance NVG-291 into a Phase 3 registrational study. We believe NVG-291 has the potential to fundamentally change the outlook for recovery and open a new world of possibilities for people living with spinal cord injury. Meaningful gains in function can help individuals rely less on caregivers and regain a greater sense of control and confidence in their everyday lives. We are grateful to the participants, families and investigators for their trust and commitment.”
NervGen achieved alignment with the FDA on RESTORE’s registrational design following its End-of-Phase 2 meeting. The Phase 3 RESTORE study builds on findings from the placebo-controlled Phase 1b/2a CONNECT SCI study, which informed the selection of primary and secondary endpoints, treatment duration, and participant-reported measures, with a focus on evaluating functional recovery and its impact on independence and quality of life.
RESTORE Study Design
RESTORE is a multicenter, randomized, double-blind, placebo-controlled Phase 3 registrational study evaluating the efficacy and safety of NVG-291 in adults living with chronic cervical motor-incomplete spinal cord injury. The study is expected to enroll approximately 150 participants across the United States and Canada.
The primary endpoint assesses improvement in hand function, a leading recovery priority for individuals with cervical SCI, as measured by GRASSP Quantitative Prehension. Secondary endpoints and blinded participant interviews will provide additional insight into functional independence and quality of life.
Eligible participants are one to ten years following a traumatic SCI, have a motor level at C7 or higher on both sides, and have an American Spinal Injury Association (ASIA) Impairment Scale classification of C or D. Participants will be randomized 1:1 to receive NVG-291 or placebo by once-daily subcutaneous injection for 12 weeks, followed by a four-week observation period. An optional 12-week open-label extension is planned following study completion. Additional information, including eligibility criteria and study locations, is available on ClinicalTrials.gov.
NVG-291 Development
NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic SCI, as observed in the Phase 1b/2a CONNECT SCI study, according to NervGen. The candidate has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. NervGen is also developing a next-generation candidate, NVG-300, as part of its pharmacologic approach to neurotraumatic and neurologic conditions.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
